Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Lymphoma 45Breast Neoplasms 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Lymphoma, Large B-Cell, Diffuse 41Lymphoma, Non-Hodgkin 39Multiple Myeloma 35Leukemia 34Leukemia, Lymphocytic, Chronic, B-Cell 32Melanoma 31Recurrence 29Leukemia, Myeloid, Acute 28Lymphoma, Follicular 27Lymphoma, B-Cell 25Ovarian Neoplasms 23Lymphoma, Mantle-Cell 23Neoplasm Metastasis 21Hematologic Neoplasms 19Myelodysplastic Syndromes 18Hodgkin Disease 18Pancreatic Neoplasms 17Burkitt Lymphoma 16Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Triple Negative Breast Neoplasms 12Lymphoma, B-Cell, Marginal Zone 12Colorectal Neoplasms 12Stomach Neoplasms 11Waldenstrom Macroglobulinemia 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Carcinoma, Hepatocellular 9

Interventions

selpercatinib 2pembrolizumab 2130-nm albumin-bound paclitaxel 2vandetanib 1trametinib 1sapanisertib 1repotrectinib 1regorafenib 1pralsetinib 1methyl N-acetylsibirosaminide 1lenvatinib 1fludarabine 1cemiplimab 1alectinib 1aldesleukin 1Thyrotropin Alfa 1Presenilin-1 1Panitumumab 1Interleukin-15 1Imatinib Mesylate 1IT-101 1IFL protocol 1Gemcitabine 1Dacarbazine 1Cyclophosphamide 1Clinical Trials, Phase II as Topic 1Cetuximab 1Capecitabine 1Camptothecin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Thyroid Neoplasms × Cyclophosphamide × Clear all
NCT02390739 2019-12-16

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
Head & Neck

Neoplasm Metastasis, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡